In The News

USA Today | February 22, 2017
“There will be a lot of major developments when it comes to this research,” Kevin Hrusovsky
Helio | February 16, 2017
The blood neurofilament light chain protein can be used to distinguish Parkinson’s disease from atypical parkinsonism disorders such as multiple system atrophy, progressive supranuclear palsy and corticobasal degeneration, according to research recently published in Neurology.
Genetic Engineering and Biotechnology News | February 14, 2017
Diverse Immuno-Oncology Approaches Call for Diverse Biomarkers
Yahoo Sports | February 8, 2017
This morning, Kuharsky issued a heartfelt request for help for his friend, Frank Wycheck. He wrote an article for ESPN about how Wycheck is suffering from CTE.
Biocompare | February 7, 2017
Traditionally, an ELISA provides such accuracy because it is so focused, using antibodies that are specific to one cytokine or particular form.
Boston Globe | February 6, 2017
Malden Catholic athletic trainer Torey Manzi administers a concussion check during a Malden-Xaverian football game in 2012.
International Business Times | February 5, 2017
Athletes who suffer a concussion show elevated levels of the protein tau in their blood, according to a new study published in Neurology last month ahead of Sunday's Super Bowl. Quanterix's Simoa technology is able to digitally parse through a wide range of substances, which allows it to find and…
Forbes | February 4. 2017
Taking advantage of ultrasensitive Simoa technology developed at Quanternix, researchers found that athletes who had a prolonged recovery after suffering a concussion had significantly higher levels of tau protein in their bloodstream at the sixth hour post injury compared with those players who…
News-Medical | February 3, 2017
An interview with Professor David Walt, Tufts University, conducted by April Cashin-Garbutt, MA
Bloomberg Businessweek | February 1, 2017
Quanterix is one of several life sciences companies racing for a way to diagnose CTE in the living.